On the afternoon of July 21, 2026, Zhou Demin, President of the Peking University Ningbo Institute of Marine Drugs, and Liao Zhongling, Director of the Digital Economy Development Bureau of Ningbo Economic and Technological Development Zone, visited Zhejiang Tianyuan Biotechnology Co., Ltd. for inspection and guidance. Huang Bisheng, Chairman of Tianyuan Biotechnology, and Jiao Mingming, General Manager, warmly received the visiting leaders and experts.

      The delegation first toured Tianyuan Biotechnology's science and technology exhibition hall, learning about the company's development history, core technological advantages, and future R&D directions. After the tour, the two sides held an in-depth discussion meeting in the conference room. At the meeting, General Manager Jiao Mingming first reported to the attending leaders on Tianyuan Biotechnology's recent basic situation and industrial layout. Subsequently, President Zhou Demin of the Peking University Ningbo Institute of Marine Drugs gave a detailed introduction to the institute's construction achievements, scientific research platform advantages, and future development plans, painting a broad prospect for industry-academia-research cooperation between the two parties.

      When discussing the company's future strategic planning, Chairman Huang Bisheng clearly stated that Tianyuan Biotechnology is committed to "building a platform-based enterprise for the development of iPSC (induced pluripotent stem cell) drugs for heart failure treatment." Huang further elaborated on the deeper logic behind this strategy: rather than focusing solely on the development of a single drug, the company aims to achieve breakthroughs in underlying technologies to build a comprehensive platform capable of continuously incubating innovative achievements and empowering clinical translation, thereby contributing a "Tianyuan solution" to heart failure treatment, a world-class medical challenge.

      Regarding Tianyuan Biotechnology's strategic layout, President Zhou Demin spoke highly of the company's dedicated innovation in cell technology, noting that cell therapy has broad prospects and expressing his hope that the two sides would engage in further exchanges on technological cooperation and industrial translation. Director Liao Zhongling of the Digital Economy Development Bureau of Ningbo Economic and Technological Development Zone also expressed strong recognition of Tianyuan Biotechnology's innovative research capabilities in the field of iPS cells. He encouraged the company to strengthen its confidence in innovation, seize the era's opportunities for the integrated development of the digital economy and biopharmaceuticals, and thoroughly deepen its core technologies.

      During the discussion, the visiting leaders offered a series of forward-looking, targeted, and actionable scientific guidance and suggestions for Tianyuan Biotechnology's future development, drawing on cutting-edge industry trends, regional industrial policies, and pain points in clinical translation. In the future, Tianyuan Biotechnology will take this visit as an opportunity to stay true to its original aspiration, accelerate the construction of the "iPSC Heart Failure Drug Development Platform," give back to society with higher-quality innovative achievements, and contribute "Tianyuan strength" to the high-quality development of the regional biopharmaceutical industry!

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and dedicated to developing drugs for heart failure treatment. With its iPS seed cell bank, tumor cell bank, and HLA compatibility matching system as cornerstones, the company has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation. Leveraging the policy advantages of Hainan's "Medical Special Zone," the company has opened up the "last mile" of clinical translation; through its regional network of facilities, it has achieved integrated operations spanning collection, preparation, R&D, and application; and with a closed-loop marketing ecosystem, it connects medical institutions, research platforms, and end users.